Galmed Pharmaceuticals Stock Performance
| GLMD Stock | USD 2.75 0.05 1.79% |
Galmed Pharmaceuticals holds a performance score of 5 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 4.51, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Galmed Pharmaceuticals will likely underperform. Use Galmed Pharmaceuticals jensen alpha, potential upside, accumulation distribution, as well as the relationship between the treynor ratio and expected short fall , to analyze future returns on Galmed Pharmaceuticals.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Galmed Pharmaceuticals are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady primary indicators, Galmed Pharmaceuticals exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 2.1 M |
Galmed |
Galmed Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 354.00 in Galmed Pharmaceuticals on August 26, 2024 and sell it today you would lose (79.00) from holding Galmed Pharmaceuticals or give up 22.32% of portfolio value over 90 days. Galmed Pharmaceuticals is currently generating 2.6568% in daily expected returns and assumes 37.6582% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Galmed, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Galmed Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Galmed Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Galmed Pharmaceuticals, and traders can use it to determine the average amount a Galmed Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0706
| Best Portfolio | Best Equity | |||
| Good Returns | GLMD | |||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 37.66 actual daily | 96 96% of assets are less volatile |
Expected Return
| 2.66 actual daily | 53 53% of assets have lower returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Galmed Pharmaceuticals is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Galmed Pharmaceuticals by adding it to a well-diversified portfolio.
Galmed Pharmaceuticals Fundamentals Growth
Galmed Stock prices reflect investors' perceptions of the future prospects and financial health of Galmed Pharmaceuticals, and Galmed Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Galmed Stock performance.
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | (8.04 M) | ||||
| Shares Outstanding | 1.66 M | ||||
| Price To Earning | (6.79) X | ||||
| Price To Book | 0.25 X | ||||
| EBITDA | (7.46 M) | ||||
| Cash And Equivalents | 22.4 M | ||||
| Cash Per Share | 0.89 X | ||||
| Total Debt | 41 K | ||||
| Debt To Equity | 0.01 % | ||||
| Book Value Per Share | 33.01 X | ||||
| Cash Flow From Operations | (6.14 M) | ||||
| Earnings Per Share | 69.72 X | ||||
| Total Asset | 16.63 M | ||||
| Retained Earnings | (192.95 M) | ||||
| Current Asset | 23.38 M | ||||
| Current Liabilities | 2.54 M | ||||
About Galmed Pharmaceuticals Performance
By analyzing Galmed Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Galmed Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Galmed Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Galmed Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel. Galmed Pharmaceutica operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 19 people.Things to note about Galmed Pharmaceuticals performance evaluation
Checking the ongoing alerts about Galmed Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Galmed Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Galmed Pharmaceuticals is way too risky over 90 days horizon | |
| Galmed Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (6.91 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Galmed Pharmaceuticals currently holds about 22.4 M in cash with (6.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Galmed Pharmaceuticals has a poor financial position based on the latest SEC disclosures |
- Analyzing Galmed Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Galmed Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Galmed Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Galmed Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Galmed Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Galmed Pharmaceuticals' stock. These opinions can provide insight into Galmed Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Galmed Stock analysis
When running Galmed Pharmaceuticals' price analysis, check to measure Galmed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galmed Pharmaceuticals is operating at the current time. Most of Galmed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Galmed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galmed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Galmed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |